![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz-300x278.jpg)
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz.jpg)
news
Bayer tops out new Leverkusen production facility
The new €275 million facility will be used to manufacture medicinal products for cancer and cardiovascular diseases and is scheduled to be ready for operation in 2024.
List view / Grid view
Drug Manufacturing
news
Fighting pharma fraud with hundreds and thousands
It seems that sprinkles, commonly known as hundreds and thousands, have undersold their capabilities, as a US scientist identifies their application could uniquely identify billions of individual tablets, potentially thwarting industry fraud.
news
Production of Novartis’ radioligand therapy suspended
Novartis has suspended production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey as it addresses potential quality issues identified in its manufacturing processes.
news
Defining best practice for continuous manufacture of OSD forms
The International Society for Pharmaceutical Engineering (ISPE) has published the Good Practice Guide: Continuous Manufacturing of Oral Solid Dosage Forms, in a bid to increase uptake.
news
ISPE announces 2022 Facility of the Year Awards winners
Winners of ISPE's Facility of the Year Awards (FOYA) 2022 include Janssen, Takeda, CRISPR Therapeutics, Catalent and Iovance Biotherapeutics.
news
Sanofi and McLaren Racing partner for manufacturing excellence
Following a successful pilot in 2021, Sanofi and McLaren Racing have decided to extend their collaboration across multiple sites in seven countries, covering more than 100 production lines, across all technologies.
article
The latest on pharmaceutical counterfeiting
Here, EPR’s Hannah Balfour discusses the latest reports on pharmaceutical counterfeiting and falsification, exploring global and European crime rates, as well as recent counterfeiting incidents reported by Big Pharma.
article
Can continuous manufacturing add shareholder value for pharmaceutical companies?
A recent empirical study of continuous manufacturing (CM) versus batch processing of US and non‑US pharmaceutical manufacturing facilities suggests that CM would be more economical than batch facilities, at least for the production of oral solid dosage products. This has significant consequences for policies and strategies to reduce supply chain…
article
Reducing downtime: acoustic emission testing of compressed air pressure vessels in pharmaceutical production
Leakage, cracking and corrosion in pressure vessels present a serious risk for operators of pharmaceutical production systems. Imminent damage must be reliably identified at an early stage to enable necessary steps to be promptly taken. Oliver Großgart, Plant Safety Expert at TÜV SÜD Industrie Service GmbH, explains how TÜV SÜD…
news
Research team discover new reaction for making tertiary amines
The new chemical reaction, a carbon-hydrogen amination cross-coupling reaction, creates a faster, simpler way of making tertiary amines without the inherent limitations of classic methods.
news
Sanofi begins construction of Singapore vaccine facility
The facility is designed around a central unit that comprises several fully digitalised modules, which can produce up to four vaccines simultaneously, regardless of the vaccine technology used.
news
Achilles Therapeutics expands manufacturing in the UK
The scale up in annual capacity and expansion of Achilles' global clinical manufacturing footprint will see its second site in the UK and first site to be established in the US.
article
The future of CMC for novel therapies
Novel and advanced therapies have come on in leaps and bounds over the past decade. Some cell and gene therapies have already reached the approvals stage, while others have now entered the later development stages. As a result, manufacturing process consistency, GMP standards and more must now meet more formal…
article
Essential requirements for autologous cellular therapies
Edward Samuel, EVP Technical Operations at Achilles Therapeutics, explains why industrialised manufacturing and scale-up of autologous cellular immunotherapies will require fully closed systems and process automation.
article
Bioprocessing/Bioproduction In-Depth Focus 2022
Download this in-depth focus to discover why closed systems and process automation are key for industrialised autologous cell therapy manufacturing and how CMC strategies for cell and gene therapies need to evolve.